A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The study will assess the efficacy of OC000459 200 mg twice daily orally in comparison to
placebo when subjects are challenged in the Vienna Challenge Chamber for 6 hours. This is a
randomised, double blind, placebo controlled, two way crossover evaluation. There will be a
screening period of up to three weeks and a washout period of at least one week between the
two treatment periods. There will be a follow up one to three weeks after the last dose of
study drug.